Search
for

    Learn

    5 / 15 results

      learn Melatonin

      hormone commonly taken for sleep aid has some topical benefits for hair

      learn HMI-115

      much-hyped research compound targeting prolactin receptor in scalp

      learn Bimatoprost

      a synthetic prostamide used to treat eyelashes also shows promise for stimulating hair growth on scalp

      learn Cyproterone

      a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

    Research

    5 / 1000+ results

    Community Join

    5 / 690 results

      community Androgenetic alopecia is a skin disease: DHT-mediated skin disorders

      in Research/Science  62 upvotes 1 year ago
      Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

      community Have you guys heard about topical melatonin?

      in Research  7 upvotes 4 years ago
      Topical melatonin may improve hair density and thickness, and reduce hair loss and seborrhea with no significant side effects. The user made their own melatonin solution for hair treatment.

      community Melatonin a possible tool to help fight AGA hair loss.

      in Research/Science  52 upvotes 3 years ago
      Topical melatonin may help reduce hair loss and increase hair thickness in people with androgenetic alopecia (AGA), with some studies showing positive results. It can be mixed with minoxidil for application, and its effectiveness might be enhanced when used with micro-needling, but results may vary among individuals.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.